2003PubMedRequires access

[High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy].

T Shimokawa, Tomohiro Kajiguchi, Minoru Saito, Yumi Kojima, Hideo Takeyama

Open publisher page 0 citations

Abstract

High-dose chemotherapy with autologous peripheral blood stem cell transplantation was administered to five patients with refractory myeloma. To collect peripheral blood stem cells, apheresis was done by administering doxorubicin 40 mg/m2 on the first day, and etoposide 60 mg/m2 on the first, second, and third days, followed by G-CSF administration to harvest cells. The high-dose chemotherapy consisted of melphalan 60 mg/m2 administered for 4 days and infusion of mononuclear cells. No serious side effects were observed during the clinical course. After transplantation, complete or partial responses were achieved. APBSCT is considered to be a useful method because it had an antitumor effect against multiple myeloma that is refractory to conventional chemotherapy, as well as against multiple myeloma that is sensitive to chemotherapy, and it can be safely performed.

About this research paper

What this paper is about

High-dose chemotherapy with autologous peripheral blood stem cell transplantation was administered to five patients with refractory myeloma. To collect peripheral blood stem cells, apheresis was done by administering doxorubicin 40 mg/m2 on the first day, and etoposide 60 mg/m2 on the first, second, and third days, followed by G-CSF administration to harvest cells. The high-dose chemotherapy consisted of melphalan 60 mg/m2 administered for 4 days and infusion of mononuclear cells. No serious side effects were observed during the clinical course. After transplantation, complete or partial responses were achieved. APBSCT is considered to be a useful method because it had an antitumor effect against multiple myeloma that is refractory to conventional chemotherapy, as well as against multiple myeloma that is sensitive to chemotherapy, and it can be safely performed.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

High-dose chemotherapy with autologous peripheral blood stem cell transplantation was administered to five patients with refractory myeloma. To collect peripheral blood stem cells, apheresis was done by administering doxorubicin 40 mg/m2 on the first day, and etoposide 60 mg/m2 on the first, second, and third days, followed by G-CSF administration to harvest cells. The high-dose chemotherapy consisted of melphalan 60 mg/m2 administered for 4 days and infusion of mononuclear cells. No serious side effects were observed during the clinical course. After transplantation, complete or partial responses were achieved. APBSCT is considered to be a useful method because it had an antitumor effect against multiple myeloma that is refractory to conventional chemotherapy, as well as against multiple myeloma that is sensitive to chemotherapy, and it can be safely performed.

Key concepts: Medicine, Multiple myeloma, Etoposide, Chemotherapy, Melphalan, Refractory (planetary science), Apheresis, Transplantation

Related papers

Back to paper searchBrowse research topicsOriginal source
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy]. — Research Paper | ScholarLens